CereScan® Demos CereMetrix® at Society for Nuclear Medicine and Molecular Imaging Annual Conference

3D Graphics

Denver (June 19, 2017) – CereScan®, a leading provider of neuro-diagnostics solutions, presented the newest features, capabilities and use cases of its CereMetrix® platform during the Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Conference at the Colorado Convention Center last week. CereMetrix® is a patented, statistically-correlated, normative and scalable medical database designed to aid in the diagnosis and treatment of the human brain.

CereMetrix® will provide the healthcare community with the most robust resource on conditions like traumatic brain injury, toxic brain injury, Alzheimer’s Disease and other dementias, PTSD, bipolar disorder, ADHD, anxiety, autism and depression. It’s a brain focused medical analytics platform that may accelerate the accurate and effective diagnosis of complex brain-related disorders to improve treatment and outcomes for patients.

“We see SNMMI members as core stakeholders for CereMetrix® and wanted to engage them to both share our vision and get feedback on the solution. I’m happy to report that the response was overwhelmingly favorable and we now feel that we are innovating in the right direction,” said John Kelley Jr., Chairman and CEO of CereScan.

The key attributes of CereMetrix® include:

  • Unique, medical database for diagnosing complex brain-related disorders based on HD functional imagery and voxel level analysis
  • Provide a highly accurate, statistically valid standardized normative dataset for comparison and correlation of related symptomology
  • Proprietary software, scalable platform, with advanced intelligence and predicative analytics capabilities
  • Robust capabilities and easy to use
  • Accelerate accurate and effective diagnosis across the range of complex brain disorders
  • Enable appropriate diagnosis and treatment

 

About CereScan®
CereScan® combines state-of-the-art brain imaging technologies with a patient-centered model of care to provide the highest level of neuro-diagnostics available. CereScan® utilizes state-of-the-art gamma camera technology, new generation imaging software and a proprietary process to produce comprehensive medical reports including voxel level images of brain function and physiology. Our functional brain imaging technologies are the most sophisticated in the world today. Additional information about the company is available at https://cerescan.com.

CereScan® and CereMetrix® are registered trademark of CereHealth Corp.

CereScan’s Latest Patent for its Neuroimaging Database Now Covers All Brain Activity Measurement Methods

CereMetrix CereScan Patent

In response to an application filed with the United States Patent and Trademark Office, CereScan® has broadened the parameters on its automated diagnostic assistance and intelligent support system, CereMetrix®, which uses quantitative measurements to assist in the diagnosis and study of complex brain disorders.  Through award of a second patent, the company may now claim exclusive use of its neuroimaging database systems and methods in the measurement of all types of brain activity.  The patent expands CereScan’s intellectual property and use of its wholly owned data warehouse, known to be the most comprehensive store of functional brain imaging data, associated patient demographic, clinical information and biomarkers worldwide.

“CereScan® is transforming the future of advanced brain diagnostics and use of intelligent learning to benefit those suffering from and studying complex brain disorders,” said John Kelley, CEO and Chairman of CereScan®. “The expansion of our patent allows us to apply key learnings to all manners of brain measurement, and vastly expands the potential for advancements in brain science using technology.”

Read More: CereScan Taps The Ohio State University to Advance Functional Brain Diagnostic System

Headquartered in Denver, CereScan® uses its patented methods, combining patient-clinical information, functional brain imaging and advanced processing software to help medical professionals identify abnormal brain physiology and activity using correlative data and pattern matching contained within its extensive data warehouse.  Through the application of technology to traditional medical practice, CereScan® has assumed a leadership role in advancing precision brain diagnostics and science.  Its first patent was awarded in September of 2014, and allowed for exclusive utilization of it systems and methods under more limited claims.

CereScan® is uniquely positioned to capitalize on a planned release of CereMetrix®, its MAaS (Medical Analytics as a Service) platform in 2017.  Its patented technology is considered by industry insiders to be a positive disruptor in the field of diagnostic radiology.  CereScan’s MAaS product suite incorporated into its CereMetrix® offering is being labeled as revolutionary, based on early feedback from Radiologists, Neurologists, and Psychiatrists who have had a chance to experiment with early release versions.

About CereScan® 
CereScan® combines state-of-the-art brain imaging technologies with a patient centered model of care to provide the highest level of neurodiagnostics anywhere. Using quantitative functional brain imaging, advanced imaging software, and an extensive library of clinical data, the CereScan medical team provides physicians with unmatched objective diagnostic information. CereScan helps patients and their physicians better understand the neurological basis of their conditions. In a variety of legal settings, CereScan provides unbiased evidence to attorneys and their clients regarding traumatic and toxic brain injuries. For researchers, CereScan provides independent pre- and post-treatment measures of organic changes in the brain along with measures of symptoms related to the brain disorder of interest. For more information, please call (866) 722-4806 or visit http://www.CereScan.com. Connect with CereScan on Twitter @CereScan and on Facebook at Facebook.com/CereScan.

About CereMetrix®

CereMetrix® is an advanced healthcare analytics ecosystem that provides radiologists, practitioners and researchers with precise data about their patient’s brain health. Each new patient’s data will be compared to a library of patients with similar brain patterns, medical histories, and clinical symptoms. The unique brain diagnostic system and ever-expanding data warehouse includes over 7,000 scan encounters, including patients’ medical histories, family histories, symptoms, prior treatments, incoming diagnoses, outgoing diagnoses, and brain scans, among other data points. Each scan is composed of over 262,000 data points that measure activity levels in up to 160 brain regions derived from comparisons to normative data.

CereScan® Extends Brain Diagnostics Services to Southern California

CereScan Southern California

CereScan, a company dedicated to providing advanced brain diagnostics to practitioners and patients, today announced its availability to residents in Southern California. Since 2009, CereScan has used its patented brain evaluation process to help medical providers and their patients find a more complete and accurate diagnosis.

CereScan’s functional brain imaging and analytical services will be offered at Imaging Healthcare Specialists (IHS) through their Encinitas facility near San Diego, California. CereScan is now partnered with nine affiliated clinics across eight states, including its most recent partner at Northwest Community Healthcare in metro Chicago. The addition of IHS expands CereScan’s national functional brain imaging network to provide services to those individuals suffering from a variety of complex, brain-based disorders – ranging from chronic traumatic brain injuries to Alzheimer’s and other dementias to toxic exposure.

“We selected IHS as our next launch partner because of their stellar reputation in the San Diego marketplace, and their use of the highest quality imaging technology. We’ve received multiple requests from across the state from medical professionals and patients seeking our statistically measured brain diagnostics process, and we are thrilled to now be able to offer those services.” said John Kelley, CEO and Chairman of CereScan. “With over 30 years of imaging services experience, IHS’s patient-focused, outpatient center is an ideal relationship.  We are honored to be partnered with them.”

Read More: CereScan Participates in Largest Brain Amyloid Scan Research Study

Headquartered in Denver, CereScan uses its patented process to combine patient clinical information, functional brain imaging and advanced processing software to help provide clarity around complex brain disorders that often have overlapping symptoms. As an example, patients with a traumatic brain injury often experience personality changes, poor concentration and fatigue, which can also be common symptoms for bipolar disorder and dementia.

Through this partnership, IHS has integrated CereScan’s patented process, using qSPECT (quantitative Single Photon Emission Computed Tomography) imaging, to assist referring physicians by clarifying non-specific symptoms to enhance the physician’s ability to accurately diagnose and have better outcomes.

Medical providers and patients interested in pursuing CereScan’s brain diagnostic process can call toll free (866) 722-4806 or email pcc@cerescan.com .

About CereScan® 
CereScan combines state-of-the-art qSPECT, qEEG and PET/CT brain imaging technologies with a patient centered model of care to provide the highest level of neurodiagnostics anywhere. Using quantitative functional brain imaging, advanced imaging software, and an extensive library of clinical data, the CereScan medical team provides physicians with unmatched objective diagnostic information. CereScan helps patients and their physicians better understand the neurological basis of their conditions. In a variety of legal settings, CereScan provides unbiased evidence to attorneys and their clients regarding traumatic and toxic brain injuries. For researchers, CereScan provides independent pre- and post-treatment measures of organic changes in the brain along with measures of symptoms related to the brain disorder of interest. For more information, please call (866) 722-4806 or visit http://www.CereScan.com. Connect with CereScan on Twitter @CereScan and on Facebook at Facebook.com/CereScan.

About Imaging Healthcare Specialists

Imaging Healthcare Specialists (IHS) is a leading outpatient provider of San Diego medical imaging services, diagnostic imaging, and radiology. Offering over 30 years of imaging services experience, IHS has earned an outstanding reputation for providing the highest quality medical imaging technology, highly specialized expertise and exceptional customer service to physicians and patients. Imaging Healthcare Specialists services southern California, including Riverside County and San Diego County.

CereScan Participates in Largest Brain Amyloid Scan Research Study

Alzheimer's IDEAS brain studyCereScan is now a registered amyloid positron emission tomography (PET) imaging site in the $100 million Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study (Ideas-Study.org). CereScan can offer Medicare-covered amyloid PET scans to study eligible Medicare patients who are referred by participating IDEAS dementia specialists (neurologists, psychiatrists and geriatric medicine physicians). The research study seeks to determine the clinical usefulness of PET imaging of brain amyloid deposits in the diagnosis of patients who are being evaluated for Alzheimer’s disease and dementia.

“Medicare will only cover these exams for seniors if done as part of clinical trial or data registry. Currently no private insurer covers amyloid PET scans for patients being evaluated for dementia or memory loss. I encourage local dementia specialists to review participation requirements, register for the trial and refer eligible patients to CereScan to get Medicare-covered amyloid PET scans that may better inform their care and future Alzheimer’s diagnosis and treatment,” said John Kelley, CereScan Chairman and Chief Executive Officer.

Diagnosing Alzheimer’s Disease is Complex

With no single test currently available, diagnosis is based on an individual’s history, physical examination and cognitive testing. Amyloid PET imaging represents a potential major advance in the assessment of people with cognitive impairment. The scan visualizes plaques present in the brain that are prime suspects in damaging and killing nerve cells in Alzheimer’s. Before amyloid PET, these plaques could only be detected by examining the brain at autopsy. The IDEAS study will follow Medicare beneficiaries to determine if amyloid PET scans may help physicians make more informed treatment decisions.

“There has never been a study of this scale to evaluate the clinical value of brain amyloid imaging in diagnosing and caring for those affected by Alzheimer’s. The dementia specialists and facilities that register for the IDEAS Study will play an essential role in engaging the nearly 19,000 individuals needed in the study and carrying out the amyloid PET scans,” said Maria Carrillo, PhD, Alzheimer’s Association chief science officer and IDEAS Study investigator.

How to Participate in the IDEAS Study

Patients cannot directly enroll in the IDEAS Study. IDEAS Study dementia specialists must enroll patients whose cases meet the study criteria and refer them to registered PET imaging facilities, such as CereScan for an amyloid PET scan. These scans will be performed and interpreted by a nuclear medicine physician or radiologist who is registered to take part in the IDEAS Study. Results will be provided to the ordering doctor for disclosure to the patient and to support further diagnostic decisions. Scan results and diagnosis will be captured for the study.

The IDEAS Study is sponsored by the American College of Radiology (ACR) and American College of Radiology Imaging Network (ACRIN), with funding and direction provided by the Alzheimer’s Association, the ACR and the manufacturers of the FDA-approved radiopharmaceuticals for amyloid imaging.

Step-by-step registration instructions are available for board-certified neurologists, psychiatrists and geriatric medicine physicians interested in enrolling eligible patients in the IDEAS Study.

Registered dementia specialists interested in referring enrolled patients to CereScan can call (866) 722-4806 or write to sstrauss@cerescan.com.